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Background. One-lung ventilation (OLV) during thoracic surgery may induce alveolar cell damage and release of proinﬂammatory
mediators. The current trial was planned to evaluate eﬀect of propofol versus isoﬂurane anesthesia on alveolar and systemic
immune modulation during thoracic surgery. Methods. Fifty adult patients undergoing open thoracic surgery were randomly
assigned to receive propofol (n = 25) or isoﬂurane (n = 25) anesthesia. The primary outcome measures included alveolar and
plasma concentrations of interleukin-8(IL-8) and tumour necrosis factor-α (TNF-α), whereas secondary outcome measures were
alveolar and plasma concentrations of malondialdehyde (MDA), superoxide dismutase (SOD), and changes in alveolar albumin
concentrations and cell numbers. Results. Alveolar and plasma concentrations of IL-8 and TNF-α were signiﬁcantly lower in the
isoﬂurane group, whereas alveolar and plasma concentrations of MDA were signiﬁcantly lower in the propofol group. Alveolar
and plasma SOD levels increased signiﬁcantly in the propofol group whereas they showed no signiﬁcant change in the isoﬂurane
group.Furthermore,theisoﬂuranegrouppatientsdevelopedsigniﬁcantlyloweralveolaralbuminconcentrationsandcellnumbers.
Conclusion. Isoﬂurane decreased the inﬂammatory response associated with OLV during thoracic surgery and may be preferable
over propofol in patients with expected high levels of proinﬂammatory cytokines like cancer patients.
1.Introduction
One-lung ventilation (OLV) during thoracic surgery may
trigger alveolar cell damage and release of proinﬂammatory
mediators that might lead to lung injury and infection in
the postoperative period [1]. A series of clinical and experi-
mental studies on mechanical ventilation reported alteration
of alveolar and systemic immunity during surgery and an-
esthesia [2–4]. Diﬀerent factors have been implicated that
include preoperative smoking or drugs, degree of surgical
trauma, preexisting lung or systemic diseases, in addition to
type and duration of anesthesia [5, 6].
Propofol has been suggested to suppress pathologic
changes associated with acute lung injury during endotox-
emiainrabbits[7].Otherexperimentalstudieshavereported
that volatile anesthetics may alter cytotoxic or phagocytic
activity of alveolar macrophages. [8]B o t hs e v o ﬂ u r a n ea n d
desﬂurane have shown ant-inﬂammatory eﬀect during tho-
racic surgery [9, 10].
The aim of this prospective, randomized, blinded clinical
trial was to assess eﬀect of propofol versus isoﬂurane an-
esthesia on alveolar and systemic immune modulation
during thoracic surgery. We hypothesized that both propofol
and isoﬂurane have similar eﬀects on lung and systemic
immunity during thoracic surgery.
2.MaterialandMethods
The current study is a prospective, randomized, double-
blinded study done on 50 adult patients ASA I-III undergo-
ingelectiveopenthoracicsurgeryusingone-lungventilation.
A written informed consent was obtained from the patients,
and institutional review board approval was obtained. All
patients were thoroughly evaluated and investigated to en-
sure ﬁtness for surgery. ECG, echocardiography, arterial
blood gases, and chest CAT scanning were performed for all
patients. Exclusion criteria included signiﬁcant lung diseases2 Anesthesiology Research and Practice
forced expiratory volume in 1s (FEV1) or vital capacity
(VC) < 50% of the predicted values, heart failure or mean
pulmonary artery pressure (MPAP)>30mmHg, coagulation
disorders or a history of preoperative immuno-suppressant
medications. All the operations were performed by the same
surgical team. Epidural analgesia was done before induction
of anesthesia at the T4–T7 level by inserting an epidural
catheter (Braun periﬁx 18ba and a microporous ﬁlter).
A test dose of 4mL 1% lidocaine with epinephrine
5μg/mL was used for verifying intrathecal or intravascular
injection, respectively. Epidural block activation was per-
formed by injecting 12mL of bupivacaine hydrochloride
0.25%. In addition, 4mL was injected 2 hours later as a
maintenance dose and every hour thereafter for postopera-
tive epidural analgesia. The patients were randomly allocated
toreceivepropofol(n = 25)orisoﬂurane(n = 25)anesthesia
using a random number table generated by Microsoft Excel.
An independent statistician was assigned to perform central
randomization to ensure proper concealment of the study
management from the patients and investigators until the
release of the ﬁnal statistical results. The patients were given
1-2mg of midazolam i.v. as a premedication about 10–
20min. before induction of anesthesia.
In the propofol group, general anesthesia was induced
with propofol 1.5–2mgkg−1 and fentanyl 3μgkg −1 in addi-
tion to cis-atracurium 0.1mgkg−1 for tracheal intubation.
Maintenance of anesthesia was done with a continuous
infusion of propofol 4–6mgkg−1 h−1 and cis-atracurium
2μgkg −1 min−1. In the isoﬂurane group, anesthesia was
induced as before but maintained with isoﬂurane 1MAC,
and cis-atracurium 2μgkg −1 min−1. In the operating room,
a radial arterial catheter and multiple peripheral intravenous
catheterswereinserted. The patients weremonitored bycon-
tinuous ECG, pulse oxymetry, capnography, central venous
pressure, and invasive blood pressure during the whole
procedure. Furthermore, arterial blood-gas tensions were
measured every hour during surgery and every four hours
thereafter. A left-sided double-lumen endobronchial tube
(DLT, Broncho-Cathw 39 or 41 Ch., Mallinckrodt Medical
Ltd, Ireland) was inserted, and a ﬁberoptic bronchoscope
was used to conﬁrm proper position of the tube. The
patients were ventilated with a VT of 10mLkg−1,f r a c t i o n
of inspired oxygen (FIO2) of 0.60 in air; the respiratory rate
was modulated to keep the end-tidal CO2 at normal values
of 35–45mmHg, and a PEEP of 5cm H2O was applied.
During one-lung ventilation (OLV), A VT of 10mLkg−1 and
FIO2 o f0 . 8t o1 . 0w a su s e dt oa c h i e v eaP a O 2 of 80mmHg,
and the respiratory rate was adjusted to keep the end-tidal
CO2 at 35–45mmHg. The peak inspiratory pressure limit
was set at 30cm H2O. Fluid and blood replacements were
adjusted to maintain patient hematocrit value above 30%.
Fluid warming and forced air warming (Bair Hugger) were
used to maintain normothermia. One analyst was blinded
in respect to the drug under study during the procedure by
covering the lines, infusion pump, gas analyzer, vaporizer,
and by numeric codes during the whole process of data
evaluation. In addition, physicians who were responsible for
postoperative care of these patients and for their discharges
from ICU and hospital were eﬀectively blinded to the study
Table 1: Patients’ demographic and operative data.
Variable
Group I
(Propofol)
No. =25
Group II
(Isoﬂurane)
No. =25
Age (y) 50.3 (13) 48.8 (14)
Sex (M/F) 18/7 17/8
Weight (kg) 77 (7.1) 75 (6.8)
Height (cm) 172 (15) 170 (12)
ASA physical status
I4 5
II 19 17
III 2 3
Type of operations:
Wedge resection 17 16
Lobectomy 6 7
Pneumonectomy 2 2
Operative time (min) 137 (43) 139 (45)
OLV time (min) 80 (34) 78 (36)
Anesthesia time (min) 152 (47) 154 (45)
Transfused units of blood/patients 10/5 11/7
Data are given as mean (SD) or numbers. ASA: American Society of
Anesthesiologists; OLV: one-lung ventilation.
protocol. The patients were kept in the ICU till restoration
to their preoperative physiological homeostasis including
stable hemodynamics, adequate ventilation, normothermia
and satisfactory pain control. Discharging from hospital was
guided by the ability to ambulate independently and to
tolerate oral feeding.
Bronchoalveolar lavage (BAL) was done by passing the
ﬁberoptic bronchoscope through the endobronchial tube.
Thetipofthescopewaswedgedintoasegmentalbronchusof
eithertherightmiddlelobeorleftlowerlobeoftheventilated
lung. Physiological saline 0.9% was used for BAL in 20mL
portions that were sequentially injected and suctioned, and
the total volume instilled was 100mL of which 55–60% was
recovered and both groups were comparable regarding the
return volume.
T h ep r i m a r yo u t c o m em e a s u r e sw e r ea l v e o l a ra n dp l a s -
maconcentrationsofinterleukin-8(IL-8)andtumournecro-
sis factor-α (TNF-α). Secondary outcome measures were
alveolarandplasmaconcentrationsofbothmalondialdehyde
(MDA) and superoxide dismutase (SOD) and changes in
alveolar albumin concentrations and cell numbers. These
parameters were recorded at three time points, after induc-
tion of anesthesia (T0), 1h after OLV (T1), 1h after sur-
gery (T2). Alveolar and blood samples were immediately
centrifuged and the supernatants separated and placed in
Eppendorf tubes and frozen at −80◦C until assay. Com-
mercial kits were used for the determination of IL-8 and
TNF-α (Test-Pig ELISA Kit; Biomed, Diepenbeek, Belgium)
based on enzyme-linked immunosorbent assay (ELISA).
Recordings were done on a plate reader (GEST, General
Elisa System Technology, Menarini Labs, Badalona, Spain)
for the automatic ELISA technique in triplicate. SerumAnesthesiology Research and Practice 3
Table 2 :C h a n g e si na l v e o l a rI L - 8 ,T N F - α, MDA, and SOD in both groups.
Time points
Group I (Propofol) No.=25 Group II (Isoﬂurane) No.=25
IL-8
(pg/mL)
TNF-α
(pg/mL)
MDA
(μmoL/litre)
SOD
(U/gHb)
IL-8
(pg/mL)
TNF-α
(pg/mL)
MDA
(μmoL/litre)
SOD
(U/gHb)
T0 331 (68) 4.7 (1.9) 0.31 (0.04) 98 (14) 328 (65) 5.0 (2.1) 0.29 (0.06) 96 (12)
T1 787 (74)†∗ 36.5 (15.1)†∗ 0.08 (0.03)†∗ 119
(16)†∗ 522 (80)‡∗ 21.1 (8.1)‡∗ 0.43 (0.09)‡∗ 100 (15)∗
T2 954 (78)†∗ 50.4 (20.4)†∗ 0.07 (0.02)†∗ 117
(15)†∗ 601 (82)‡∗ 26.3 (12.4)‡∗ 0.46 (0.13)‡∗ 101 (14)∗
IL-8: interleukin-8; TNF-α:t u m o u rn e c r o s i sf a c t o r - α; MDA: malondialdehyde; SOD: superoxide dismutase. Data are expressed as mean (SD). †P<0.05
within the propofol group, ‡P<0.05 within the isoﬂurane group, ∗P<0.05 between both groups.
Table 3: Changes in plasma IL-8, TNF-α, MDA, and SOD in both groups.
Time points
Group I (Propofol) No.=25 Group II (Isoﬂurane) No.=25
IL-8
(pg/mL)
TNF-α
(pg/mL)
MDA
(μmoL/litre)
SOD
(U/gHb)
IL-8
(pg/mL)
TNF-α
(pg/mL)
MDA
(μmoL/litre)
SOD
(U/gHb)
T0 2.5 (0.4) 21 (5) 2.8 (1.2) 532 (54) 2.4 (0.5) 23 (6) 2.7 (1.0) 538 (62)
T1 16 (2.4)†∗ 95 (24)†∗ 1.8 (0.5)†∗ 644 (58)†∗ 9.1 (1.4)‡∗ 77 (19)‡∗ 4.1 (1.6)‡∗ 542 (70)∗
T2 13.4 (2.9)†∗ 293 (53)†∗ 1.7 (0.4)†∗ 640 (57)†∗ 7.9 (2.4)‡∗ 151 (41)‡∗ 4.4 (1.3)‡∗ 543 (69)∗
IL-8: interleukin-8; TNF-α:t u m o u rn e c r o s i sf a c t o r - α; MDA: malondialdehyde; SOD: superoxide dismutase. Data are expressed as mean (SD). †P<0.05
within the propofol group, ‡P<0.05 within the isoﬂurane group, ∗P<0.05 between both groups.
MDA assay: the measurement obtained may reﬂect some
combination of free and bound MDA already present in the
sample [11]. Measurement of SOD activity was performed
through detection of pyrogallol auto-oxidation [12]. Albu-
min concentration in the alveoli was determined by using
nephelometry, whereas changes in alveolar cell numbers
were evaluated electronically by using a Coulter Counter
(Industrial model D).
Furthermore, arterial blood gases and airway pressures
were recorded at the following time points: during two-lung
ventilation, during one-lung ventilation, and after one-lung
ventilation. In addition, postoperative outcome was reported
in both groups regarding incidence of atelectasis requiring
bronchoscopy, pneumonia, ARDS (adult respiratory distress
syndrome), respiratory failure requiring ventilation, oxygen
need at hospital discharge, 30-day mortality, total number of
complications, in addition to ICU and hospital stay times.
3. Statistics
With a 2-sided type I error of 5% and study power at 80%,
a mean sample size of 25 patients in each group was found
enough to detect diﬀerences in alveolar and plasma cytokine
concentrations between propofol and isoﬂurane anesthesia
according to a previous study [10]. Continuous variables
were reported as mean (standard deviation) and categorical
variables were expressed as percentages. Statistical analyses
were performed using Statistica for Windows version 10.0
software. The Kolmogorov-Smirnov test was used to verify
normal distribution of data. Distribution of residuals testing
was performed to conﬁrm that ANOVA was appropriate to
our data. Data were analyzed on an intention to treat basis
using two-way analysis of variance (ANOVA) for repeated
measures. This was followed by Student-Newman-Keuls test,
if a diﬀerence between groups had been detected. Changes
over time in nonnormally distributed data sets were analyzed
by Friedman repeated measures ANOVA on ranks. P<0.05
was considered statistically signiﬁcant.
4. Results
Both groups were comparable regarding the patients, demo-
graphic and operative data (Table 1).
Alveolar and plasma concentrations of IL-8, TNF-α
increased signiﬁcantly in both groups, however, they were
signiﬁcantly lower in the isoﬂurane group (Tables 2 and 3).
Moreover,alveolaralbuminconcentrationsandcellnumbers
increased signiﬁcantly in both groups but were signiﬁcantly
lower in the isoﬂurane group (Table 4).
Both alveolar and plasma MDA levels increased signiﬁ-
cantlyinpatientsexposedtoisoﬂuraneandweresigniﬁcantly
higher than in patients receiving propofol who developed
decrease in MDA levels. Furthermore, alveolar and plasma
SOD levels increased signiﬁcantly in the propofol group
where-as they showed no signiﬁcant change in patients
exposed to isoﬂurane (Tables 2 and 3).
Both groups were comparable in respect to arterial blood
gases and airway pressures during surgery (Table 5).
Total number of complications was signiﬁcantly lower in
the isoﬂurane group and both ICU and hospital stay time
were signiﬁcantly lower in the isoﬂurane group (Table 6).
5. Discussion
The current study has demonstrated that OLV during tho-
racic surgery induced alveolar and systemic inﬂammatory4 Anesthesiology Research and Practice
Table 4: Changes in alveolar albumin concentrations and cell numbers in both groups.
Time points Group I (Propofol) No.=25 Group II (Isoﬂurane) No.=25
albumin (μg/mL) Cells (×106/mL) albumin (μg/mL) Cells (×106/mL)
T0 20 (9) 0.07 (0.05) 19 (8) 0.06 (0.04)
T1 101 (31)†∗ 0.19 (0.09)†∗ 51 (15)‡∗ 0.11 (0.07)‡∗
T2 121 (44)†∗ 0.21 (0.10)†∗ 78 (30)‡∗ 0.12 (0.06)‡∗
Data are expressed as mean (SD). †P<0.05 within the propofol group, ‡P<0.05 within the isoﬂurane group, ∗P<0.05 between both groups.
Table 5: Arterial blood gases and airway pressures in both groups.
Variable Group I (Propofol) No.=25 Group II (Isoﬂurane) No.=25
During TLV During OLV After OLV During TLV During OLV After OLV
PaO2 (mmHg) 268 (88) 115 (54) 284 (87) 265 (86) 111 (51) 278 (88)
PaCO2 (mmHg) 35.6 (3.9) 36.2 (4.2) 35.5 (4.0) 36.4 (3.8) 36.9 (3.9) 36.1 (4.0)
pH 7.41 (0.04) 7.40 (0.04) 7.41 (0.04) 7.40 (0.04) 7.40 (0.05) 7.40 (0.04)
SaO2 (%) 99.1 (1.3) 96.2 (2.5) 99.3 (1.2) 99.0 (1.1) 95.7 (2.2) 98.7 (1.5)
Ppeak (cm H2O) 17.6 (5.1) 24.4 (5.3) 17.2 (3.9) 18.2 (5.4) 25.2 (4,9) 17.6 (4.1)
Pmean (cm H2O) 6.1 (2.0) 8.9 (2.2) 6.0 (1.2) 6.4 (1.8) 9.2 (2.1) 6.3 (1.3)
Pplateau (cm H2O) 13.8 (2.9) 17.1 (3.9) 13.6 (2.2) 14.0 (2.7) 17.5 (3.8) 13.9 (2.4)
TLV: two-lung ventilation; OLV: one-lung ventilation; PaO2:a rt e ri a lo x y g e nt e n s i o n ;P a C O 2: arterial carbon dioxide tension; SaO2: arterial oxygen saturation;
Ppeak: peak inspiratory pressure; Pmean: mean inspiratory pressure; Pplateau: plateau inspiratory pressure. Data are expressed as mean (SD). P>0.05
denotes statistical insigniﬁcance.
reaction. This immune reaction was less in patients ex-
posed to isoﬂurane anesthesia when compared to propofol
anesthesia as indicated by lower alveolar and plasma concen-
trations of IL-8 and TNF-α. Furthermore, alveolar albumin
concentrations and cell numbers were less in patients who
received isoﬂurane anesthesia. However, MDA was higher
and SOD was less in patients exposed to isoﬂurane. Anes-
thesia,surgery,andOLVinduceaninﬂammatoryresponsein
alveolarmacrophagesthatleadtoreleaseofproinﬂammatory
cytokines into alveoli and systemic circulation [13]. These
cytokineshavevariousactionsthatincludeimmunemodula-
tions and control of tissue infection, injury, and healing [14].
Controlled release of IL-8, TNF-α play an important role in
ﬁghting against infection; however, the uncontrolled release
of these cytokines triggers massive inﬂux of neutrophils and
granulocytes with subsequent lung injury and dysfunction
[15]. MDA is an indicator of lipid peroxidation, whereas
SOD is an antioxidant enzyme that helps in scavenging free
radicals which play a role in tissue injury [16].
The protective eﬀects of inhalational anesthetics on the
heart have been approved, however, there are no enough
data regarding the potential beneﬁt to the lung during
thoracic surgery [17]. Our ﬁndings were matching with
the results stated by Cho and colleagues [9], who reported
that volatile anesthetics attenuate alveolar and systemic
inﬂammatory response triggered by the heart lung machine.
In another study [18], alveolar secretion of inﬂammatory
cytokines in primary culture has been attenuated by inhala-
tional anesthetics. Similarly, De Conno and coworkers [19],
reported anti-inﬂammatory eﬀect of the volatile anesthetic
sevoﬂurane at the lung in patients undergoing thoracic
surgery and linked this eﬀect to improved postoperative
outcome and 50% reduction of postoperative complications
related to lung injury when compared with propofol. In
another study [20], volatile anesthetic attenuated the release
of inﬂammatory cytokines from the alveoli in a model of
lipopolysaccharide-induced injury in rats. Furthermore, Re-
uterhaus and coworkers [21] demonstrated ability of isoﬂu-
rane in reducing release of inﬂammatory mediators in an
endotoxin-induced lung injury model.
In contrast to our results, other studies have demon-
strated augmentation of the release of alveolar inﬂammatory
mediators by volatile anesthetics during mechanical ventila-
tion in both rats and pigs [22, 23]. These contradictory ﬁnd-
ings may be explained by variations in patient populations,
use of diﬀerent inhalational anesthetics and variations in the
exposure time, diﬀerent methods of biochemical analysis,
and absence of settled dilution markers. Furthermore, the
interpretationofalveolarinﬂammatorymediatorsintheBAL
ﬂuid is debatable and diﬃcult as an unknown fraction of
the mediators remains inside the cells in addition to the
possibility of cell injury during the procedure of BAL.
In our study, MDA levels were signiﬁcantly higher in
patients exposed to isoﬂurane whereas SOD levels were
signiﬁcantly higher in the propofol group which imply
increasedantioxidantcapacityinpatientsreceivingpropofol.
However, a high antioxidant capacity may not be a nice
event if it denotes a reaction to an increased oxidative
stress. Therefore, evaluation of the antioxidant status must
be linked in a dynamic manner to the circumstances under
which it is measured. It should be noticed that increased
inﬂammatory mediators in alveoli may not bear major clin-
icalimplicationsinhealthysubjects;howeverinpatientswith
expected high levels of inﬂammatory cytokines like cancer
and chronic renal failure patients, the proper selection of the
anesthetic may be highly important.Anesthesiology Research and Practice 5
Table 6: Postoperative outcome in both groups.
Variable Group I (Propofol) No.=25 Group II (Isoﬂurane) No.=25 P value
Atelectasis requiring bronchoscopy 5 2 0.22
Pneumonia 4 1 0.16
ARDS 0 0 N/A
Respiratory failure requiring ventilation 1 0 0.31
Oxygen need at hospital discharge 0 0 N/A
30-day mortality 0 0 N/A
Total number of complications 10 3 0.02∗
ICU stay (hours) 37 (7) 26 (8) 0.02∗
Hospital stay (days) 11 (5) 7 (4) 0.03∗
ARDS: Adult respiratory distress syndrome; ICU: Intensive care unit; N/A: Not applicable.
Data are expressed as numbers or as mean (SD). ∗P<0.05 between both groups.
In conclusion, our study has shown anti-inﬂammatory
eﬀect of the volatile anesthetic isoﬂurane in patients under-
going thoracic surgery with OLV that may have clinical
implications in situations of expected high inﬂammatory
mediators like cancer patients. Furthermore, the overall
postoperative outcome was signiﬁcantly better in patients
receiving isoﬂurane anesthesia.
Acknowledgment
The authors thank clinical pathology department, Minouﬁya
University for the eﬀort in doing the laboratory work. None
of the authors has any conﬂict of interests.
References
[1] T. Schilling, A. Kozian, C. Huth et al., “The pulmonary im-
mune eﬀects of mechanical ventilation in patients undergoing
thoracic surgery,” Anesthesia and Analgesia, vol. 101, no. 4, pp.
957–965, 2005.
[2] O. M. Frass, F. B¨ uhling, M. T¨ ager et al., “Antioxidant and
antiprotease status in peripheral blood and BAL ﬂuid after
cardiopulmonary bypass,” Chest, vol. 120, no. 5, pp. 1599–
1608, 2001.
[3] N. Kotani, C. Y. Lin, J. S. Wang et al., “Loss of alveolar
macrophages during anesthesia and operation in humans,”
Anesthesia and Analgesia, vol. 81, no. 6, pp. 1255–1262, 1995.
[4] D. Dreyfuss and G. Saumon, “Ventilator-induced lung injury:
lessons from experimental studies,” American Journal of
RespiratoryandCriticalCareMedicine,vol.157,no.1,pp.294–
323, 1998.
[5] N. Kotani, H. Hashimoto, D. I. Sessler et al., “Smoking
decreasesalveolarmacrophagefunctionduringanesthesiaand
surgery,” Anesthesiology, vol. 92, no. 5, pp. 1268–1277, 2000.
[ 6 ]S .R .C r a i g ,H .A .L e a v e r ,P .L .Y a p ,G .C .P u g h ,a n dW .S .
Walker, “Acute phase responses following minimal access and
conventional thoracic surgery,” European Journal of Cardio-
Thoracic Surgery, vol. 20, no. 3, pp. 455–463, 2001.
[7] Y. Takao, K. Mikawa, K. Nishina, and H. Obara, “Attenuation
ofacutelunginjurywithpropofolinendotoxemia,” Anesthesia
and Analgesia, vol. 100, no. 3, pp. 810–816, 2005.
[8] N. Kotani, S. Takahashi, D. I. Sessler et al., “Volatile anes-
thetics augment expression of proinﬂammatory cytokines
in rat alveolar macrophages during mechanical ventilation,”
Anesthesiology, vol. 91, no. 1, pp. 187–197, 1999.
[ 9 ] E .J .C h o ,J .H .Y o o n ,S .J .H o n g ,S .H .L e e ,a n dS .B .S i m ,“ T h e
eﬀects of sevoﬂurane on systemic and pulmonary inﬂam-
matory responses after cardiopulmonary bypass,” Journal of
Cardiothoracic and Vascular Anesthesia, vol. 23, no. 5, pp. 639–
645, 2009.
[10] T. Schilling, A. Kozian, M. Kretzschmar et al., “Eﬀects of
propofol and desﬂurane anaesthesia on the alveolar inﬂam-
matory response to one-lung ventilation,” British Journal of
Anaesthesia, vol. 99, no. 3, pp. 368–375, 2007.
[ 1 1 ]S .H .Y .W o n g ,J .A .K n i g h t ,S .M .H o p f e r ,O .Z a h a r i a ,C .
N. Leach, and F. W. Sunderman, “Lipoperoxides in plasma
as measured by liquid-chromatographic separation of mal-
ondialdehyde-thiobarbituric acid adduct,” Clinical Chemistry,
vol. 33, no. 2, pp. 214–220, 1987.
[12] S. Marklund and G. Marklund, “Involvement of the super-
oxide anion radical in the autoxidation of pyrogallol and a
convenient assay for superoxide dismutase,” European Journal
of Biochemistry, vol. 47, no. 3, pp. 469–474, 1974.
[13] H. Wrigge, J. Zinserling, F. Stuber et al., “Eﬀects of mechanical
ventilation on release of cytokines into systemic circulation
in patients with normal pulmonary function,” Anesthesiology,
vol. 93, no. 6, pp. 1413–1417, 2000.
[14] N. Kotani, H. Hashimoto, D. I. Sessler et al., “Intraoperative
modulation of alveolar macrophage function during isoﬂu-
rane and propofol anesthesia,” Anesthesiology,v o l .8 9 ,n o .5 ,
pp. 1125–1132, 1998.
[15] K. Kooguchi, S. Hashimoto, A. Kobayashi et al., “Role of
alveolar macrophages in initiation and regulation of inﬂam-
mation in Pseudomonas aeruginosa pneumonia,” Infection
and Immunity, vol. 66, no. 7, pp. 3164–3169, 1998.
[16] M. N. Ahmed, C. Codipilly, N. Hogg, and R. L. Auten, “The
protective eﬀect of overexpression of extracellular superoxide
dismutase on nitric oxide bioavailability in the lung after
exposuretohyperoxiastress,”ExperimentalLungResearch,vol.
37, no. 1, pp. 10–17, 2011.
[17] K. Tanaka, L. M. Ludwig, J. R. Kersten, P. S. Pagel, and
D. C. Warltier, “Mechanisms of cardioprotection by volatile
anesthetics,” Anesthesiology, vol. 100, no. 3, pp. 707–721, 2004.
[18] O. Giraud, S. Molliex, C. Rolland et al., “Halogenated an-
esthetics reduce interleukin-1 β-induced cytokine secretion by
rat alveolar type II cells in primary culture,” Anesthesiology,
vol. 98, no. 1, pp. 74–81, 2003.6 Anesthesiology Research and Practice
[19] E. De Conno, M. P. Steurer, M. Wittlinger et al., “Anesthetic-
induced improvement of the inﬂammatory response to one-
lung ventilation,” Anesthesiology, vol. 110, no. 6, pp. 1316–
1326, 2009.
[20] D.Suter,D.R.Spahn,S.Blumenthaletal.,“Theimmunomod-
ulatory eﬀect of sevoﬂurane in endotoxin-injured alveolar
epithelial cells,” Anesthesia and Analgesia, vol. 104, no. 3, pp.
638–645, 2007.
[21] J. Reutershan, D. Chang, J. K. Hayes, and K. Ley, “Protective
eﬀects of isoﬂurane pretreatment in endotoxin-induced lung
injury,” Anesthesiology, vol. 104, no. 3, pp. 511–517, 2006.
[22] N. Kotani, S. Takahashi, D. I. Sessler et al., “Volatile anes-
thetics augment expression of proinﬂammatory cytokines
in rat alveolar macrophages during mechanical ventilation,”
Anesthesiology, vol. 91, no. 1, pp. 187–197, 1999.
[23] R. S.K. Takala, H. R. Soukka, M. S. Salo et al., “Pulmonary
inﬂammatory mediators after sevoﬂurane and thiopentone
anaesthesia in pigs,” Acta Anaesthesiologica Scandinavica, vol.
48, no. 1, pp. 40–45, 2004.